Calendario›GILD›Magrolimab · ELEVATE CRC

Magrolimab · ELEVATE CRC

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Ensayo de GILEAD SCIENCES, INC. en Cancer colorrectal metastasico.

Más ensayos de: Cáncer colorrectal metastásico.

Fase

Fase 2

Estado

Interrumpido

Participantes

77

previstos

Centros

51

Fin del objetivo primario

jun 2024

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en jul 2022.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor decision to terminate study».

Qué mide

Safety Run-in Cohort: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (First dose date up to 28 days) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC). The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

Más ensayos de GILD

Todos los de GILD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05330429), actualizada en jun 2025.